PharmExec Direct:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 
December 1, 2011 | ISSUE NUMBER 228 VOL 8

Production
A Simple Plan (to Save US Pharma Manufacturing)
Pharmaceutical manufacturing in the US is in rapid decline. Fernando Muzzio and Mauricio Futran propose a plan to turn it around ...Read More

Europe
GSK Voices More Concerns over Europe
Andrew Witty’s comments to the UK’s High Pay Commission reflect his growing concerns with the business climate in Europe ...Read More

Advertising
The Rx Club Show's 25th Anniversary
Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year? ...Read More

Safety
Let's Fight Adulteration with Information
Erik Greb discusses the Government Accountability Office’s proposal for an information clearinghouse, through which companies could share information anonymously on adulterated ingredients with FDA and other companies
...Read more

// Eli Lilly appointed Richard Ascroft as Senior Director, Corporate Affairs, for the Australia, Canada, and Europe (ACE) region. // Sage Therapeutics (Boston) announced the appointment of Albert J. Robichaud, PhD, to Chief Scientific Officer. // Areta L. Kupchyk joined Nixon Peabody's Life Sciences and Health Services practices team (Washington). Kupchyk brings 18 years of experience working at the FDA. // The Society of Pharmaceutical and Biotech Trainers (Roanoke, Va.) announced that Jim Trunick has been elected Vice President of its Board of Directors, effective January 1, 2012.

Dec. 5–6: FT Global Pharmaceutical and Biotechnology Conference 2011
London, UK


Dec. 5–8: KOL & Stakeholder Engagement USA 2011
Philadelphia. PA


Dec. 9: Key Influencers and their Networks in Hematology
San Diego, CA


Feb. 28–29: Global Transparency Congress
London, UK



 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook
 


 
Survey
Do you support a generic-drug user fee for industry?
Click To Vote
 
Quick Links

Clinical Trials: Dutch Scandal Puts New Emphasis on Fraud Prevention

House Bill Would Stiffen Penalties for Drug Counterfeiters

Achieving That First $1 Billion


User Management
| Subscribe | Update My Profile | Advertise With Us | Visit PharmExec.com |

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.

 
Visit Pharmaceutical Executive